The Tofacitinib Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Tofacitinib Market:

https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

According to The Business Research Company’s Tofacitinib Global Market Report 2024, The tofacitinib market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.12 billion in 2024 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to clinical efficacy and trials, regulatory approvals, rise in incidence of targeted conditions, physician prescribing patterns, patient acceptance..

The tofacitinib market size is expected to see rapid growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expanded indications, market access initiatives, competitive landscape, real-world evidence, patient-centric healthcare.. Major trends in the forecast period include focus on pediatric rheumatoid arthritis treatment, exploration of tofacitinib in dermatological conditions, strategic collaborations and partnerships, integration of real-world evidence in treatment guidelines, focus on personalized medicine approaches..

The rise in the prevalence of rheumatoid arthritis is expected to propel the growth of the tofacitinib market going forward. Rheumatoid arthritis is an autoimmune, inflammatory disorder that affects the hands, feet, other joints, and internal organs. Tofacitinib medications involve the Janus kinase enzymes from contributing to the inflammation that results in the symptoms of rheumatoid arthritis by preventing their activity. For instance, in February 2022, according to the National Arthritis Data Workgroup, a US-based consortium of experts in epidemiology, over 52.5 million adult Americans, or more than 22% of the population, had been diagnosed with arthritis or another rheumatic disease. Adults aged 18 and older with arthritis are predicted to reach 67 million by 2030. Therefore, the rise in the prevalence of rheumatoid arthritis is driving the growth of the tofacitinib market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10779&type=smp

The tofacitinib market covered in this report is segmented –

1) By Drug Class: Antirheumatic, Janus Kinase Inhibitor, Immunosuppressant

2) By Strength: 5mg, 10mg, 11mg, 22mg

3) By Route Of Administration: Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By Application: Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Other Applications

Product innovation is a key trend gaining popularity in the tofacitinib market. Major companies operating in the tofacitinib market are developing innovative products to sustain their position in the market. For instance, in December 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, announced that U.S. Food and Drug Administration (FDA) approved supplemental New Drug Application (sNDA) for tofacitinib-based medications XELJANZ and XELJANZ XR. XELJANZ is the first and only Janus kinase (JAK) inhibitor authorized in the United States for five immuno-inflammatory diseases. A Phase 3 multicenter, randomized, double-masked, placebo-controlled research comparing the safety and efficacy of tofacitinib 5 mg twice daily to a placebo in 269 adult patients with active AS formed the basis for the approval of XELJANZ for the treatment of AS.

The tofacitinib market report table of contents includes:

Executive Summary
Tofacitinib Market Characteristics
Tofacitinib Market Trends And Strategies
Tofacitinib Market - Macro Economic Scenario
Global Tofacitinib Market Size and Growth
.

.

.

Global Tofacitinib Market Competitive Benchmarking
Global Tofacitinib Market Competitive Dashboard
Key Mergers And Acquisitions In The Tofacitinib Market
Tofacitinib Market Future Outlook and Potential Analysis
Appendix
Top 5 Major Key Players Are:

Beacon Pharmaceuticals Limited
Pfizer Inc
Globe Pharmaceuticals Ltd
Drug International Limited
Dolphin Pharmaceuticals
Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]



Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model